Interim analysis of data from a long-term, extension trial of tafamidis meglumine in patients with transthyretin amyloid cardiomyopathy

被引：0

作者：

Elliott, P. ^{[1
]}

Drachman, B. M. ^{[2
]}

Gottlieb, S. S. ^{[3
]}

Hoffman, J. E. ^{[4
]}

Hummel, S. L. ^{[5
]}

Lenihan, D. J. ^{[6
]}

Ebede, B. ^{[7
]}

Gundapaneni, B. ^{[8
]}

Schwartz, J. H. ^{[9
]}

Sultan, M. B. ^{[9
]}

Shah, S. J. ^{[10
]}

机构：

[1] UCL, London, England

[2] Univ Penn, Penn Presbyterian Med Ctr, Hlth Syst, Philadelphia, PA USA

[3] Univ Maryland, Sch Med, Baltimore, MD 21201 USA

[4] Univ Miami, Miami, FL USA

[5] Univ Michigan, Ann Arbor, MI 48109 USA

[6] Washington Univ, Sch Med, St Louis, MO USA

[7] Pfizer Inc, Collegeville, PA USA

[8] Pfizer Inc, Groton, CT USA

[9] Pfizer Inc, New York, NY USA

[10] Northwestern Univ, Feinberg Sch Med, Div Cardiol, Dept Med, Chicago, IL 60611 USA

来源：

EUROPEAN HEART JOURNAL | 2019年 / 40卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1169

引用

页码：645 / 645

页数：1

共 50 条

[21] Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy
Teresa Coelho
Luis F. Maia
Ana Martins da Silva
Márcia W. Cruz
Violaine Planté-Bordeneuve
Ole B. Suhr
Isabel Conceiçao
Hartmut H.-J. Schmidt
Pedro Trigo
Jeffery W. Kelly
Richard Labaudinière
Jason Chan
Jeff Packman
Donna R. Grogan
Journal of Neurology, 2013, 260 : 2802 - 2814
[22] Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT])
Miller, Alan B.
Januzzi, James L.
O'Neill, Blair J.
Gundapaneni, Balarama
Patterson, Terrell A.
Sultan, Marla B.
Lopez-Sendon, Jose
AMERICAN JOURNAL OF CARDIOLOGY, 2021, 148 : 146 - 150
[23] Reply to the letter regarding the article 'Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study'
Damy, Thibaud
Sultan, Marla B.
Witteles, Ronald
EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 (06) : 1057 - 1058
[24] Long- term tafamidis efficacy in patients with transthyretin amyloid cardiomyopathy by baseline left ventricular ejection fraction
Drachman, Brian
Damy, Thibaud
Hanna, Mazen
Wang, Rong
Angeli, Franca S.
Garcia-Pavia, Pablo
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2024, 31 : S4 - S4
[25] Tafamidis treatment for transthyretin amyloid cardiomyopathy: results from an open-label, early-access, long-term study extension in an all-comers population
Crespo-Leiro, M. G.
Hanna, M.
Damy, T.
Delgado, D.
Ebede, B.
Angeli, F. S.
Maurer, M. S.
Garcia-Pavia, P.
Drachman, B. M.
EUROPEAN HEART JOURNAL, 2024, 45
[26] HEALTH IMPACT OF TAFAMIDIS IN TRANSTHYRETIN AMYLOID CARDIOMYOPATHY PATIENTS: AN ANALYSIS FROM THE ATTR-ACT AND THE OPEN-LABEL EXTENSION STUDIES
Rozenbaum, M. H.
Garcia, A.
Grima, D.
Tran, D.
Bhambri, R.
Stewart, M.
Li, B.
Heeg, B.
Postma, M.
Masri, A.
VALUE IN HEALTH, 2020, 23 : S487 - S487
[27] Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis
Wang, Jie
Chen, Hongyu
Tang, Zihuan
Zhang, Jinquan
Xu, Yuanwei
Wan, Ke
Hussain, Kifah
Gkoutos, Georgios, V
Han, Yuchi
Chen, Yucheng
ECLINICALMEDICINE, 2023, 63
[28] Tafamidis in patients with severe heart failure due to transthyretin amyloidosis cardiomyopathy: improved long-term survival
Tubben, Alwin
Nienhuis, Hans L. A.
van der Meer, Peter
EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 (11) : 2065 - 2066
[29] Long-term Treatment with Inotersen for Amyloid Transthyretin Amyloidosis Cardiomyopathy
Dasgupta, Noel
Benson, Merrill
JOURNAL OF CARDIAC FAILURE, 2018, 24 (08) : S59 - S59
[30] Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study
Violaine Planté-Bordeneuve
Farida Gorram
Hayet Salhi
Tarik Nordine
Samar S. Ayache
Philippe Le Corvoisier
Daniel Azoulay
Cyrille Feray
Thibaud Damy
Jean-Pascal Lefaucheur
Journal of Neurology, 2017, 264 : 268 - 276

← 1 2 3 4 5 →